OPTHEA LIMITED (OPT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OPT - OPTHEA LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index: ALL-ORDS

Opthea is an Australian healthcare company specialising in the development and commercialisation of therapies to combat eye diseases. Founded in 1984, the company listed on the ASX in 1991.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.69

15 Apr
2024

-0.030

OPEN

$0.71

-4.17%

HIGH

$0.72

451,013

LOW

$0.69

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-45.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.2 M
Book Value Per Share xxxxxxxxxxxxxxx-1.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-179.3 M
Net Profit Margin xxxxxxxxxxxxxxx-131,469.74 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-694.96 %
Return on Invested Capital xxxxxxxxxxxxxxx-693.52 %
Return on Assets xxxxxxxxxxxxxxx-179.93 %
Return on Equity xxxxxxxxxxxxxxx-694.96 %
Return on Total Capital xxxxxxxxxxxxxxx-729.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-179.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx134 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx20.25 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx223 M
Research & Development xxxxxxxxxxxxxxx182 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

OPT STOCK CHART